Search

Purpose: To investigate the influence of N-acetylcysteine (NAC) aerosol inhalation on serum inflammatory factors and immune function in children with upper airway cough syndrome (UACS). Methods: 118 children with UACS who were on admission at Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine, China between September 2021 and February 2023, were enrolled in the study. They were assigned to control and study cohorts, with 59 patients per group. Control group received routine treatment (3 mL of normal saline via nebulized inhalation 2 times/day), while the study group received 3 mL of NAC aerosol inhalation via nebulized inhalation 2 times/day. Both groups were treated for 2 weeks. Thereafter, the two groups were compared with respect to total treatment effectiveness, cough symptom and Lund-Kennedy ratings, levels of inflammatory factors (interleukin-13 (IL-13), interleukin-27 (IL-27), C-reactive protein (CPR)) and concentrations of immune function indices (CD3 +, CD4 + and CD8 +) before and after treatment, and adverse reactions. Results: Treatment effectiveness (efficacy) was significantly higher (p < 0.05) in study cohort than in control cohort (89.83 vs 71.19 %). The 2 cohorts had significant reductions in scores on cough symptoms and Lund-Kennedy, with smaller values in study cohort. In both groups, the levels of IL-13 and CPR were decreased, while IL-27 level was increased. Levels of IL-13 and CPR in study group were significantly lower than those in control group, while IL-27 level was significantly higher than that in control group (p < 0.05). Conclusion: N-acetylcysteine aerosol inhalation enhances curative effect, relieves clinical symptoms, reduces inflammation, and improves immunity in UACS children, and shows good degree of safety. However, its long-term efficacy needs to be studied. [ABSTRACT FROM AUTHOR]

Introduction: Cough is a major symptom of respiratory and some non-respiratory ailments for which patients usually seek primary medical care. Homoeopathy is frequently used for treatment of chronic cough. Objective: This study aims to assess whether homoeopathy is useful for treating chronic cough resulting from Upper airway cough syndrome (UACS), Asthma and related syndromes, or Gastroesophageal reflux disease (GERD). Study Design: A multi-centre, prospective, observational cohort study was design. Study setting: The study was conducted in the outpatient departments of 10 centres of Central Council for Research in Homoeopathy, India from May 2018 - June 2020. Patients: The study enrolled patients of any gender, between 7-65 years of age, presenting cough lasting >8 weeks. Main Outcome Measure(s): Cough Severity Index (CSI) and EQ-5D-5L scales were used to analyse the outcomes. Results: Out of 2397 patients screened, only 706 cases with minimum four follow ups were studied on modified Intention to Treat (mITT) basis. The outcomes of the study were analysed by CSI and EQ-5D-5L scores. The mean of the CSI score at baseline was 19.09 while it reduced to 3.89 in the eighth follow-up with p value p-value<0.05. Phosphorus, Arsenic album, Pulsatilla, Sulphur, Lycopodium and Silica were found to be the most often prescribed medicines. [ABSTRACT FROM AUTHOR]

Background: Refractory chronic cough (RCC) causes significant impairments in the life quality of patients. Further research into the identification of etiologies and development of the treatment schedules for RCC is needed., Patients and Methods: We established an multidisciplinary team (MDT) clinic, by integrating respiratory medicine, otorhinolaryngology, and gastroenterology departments, to investigate cough etiologies and the effectiveness of treatment. The therapeutic effect was assessed quantitatively using the Cough Visual Analog Scales (VAS), Leicester Cough Questionnaire (LCQ), and Reflux Symptoms Index (RSI) scores., Results: In total, 213 patients attending the MDT outpatient clinic were examined, and 115 patients with RCC were included for analysis. The RCC diagnosis rate among the outpatient was 88.7%. Common causes of RCC included gastroesophageal reflux cough (63.5%), upper airway cough syndrome (UACS) (43.5%), and cough variant asthma (CVA) (14.8%). After an average treatment period of 2.17 ± 1.06 weeks (wk), 73.9% of the patients had partial cough remission, and 6.1% had complete cough remission. The cough VAS score before and after treatment was 6.11 ± 2.02 vs. 3.66 ± 2.22 (P < 0.05), respectively; LCQ total score before and after treatment was 10.24 ± 3.11 vs. 13.16 ± 3.59 (P < 0.05), respectively; and RSI score before and after treatment was 15.82 ± 7.01 vs. 10.71 ± 6.64 (P < 0.05), respectively., Conclusion: The etiologies of most patients with RCC could be identified in the MDT clinic, and the cough-related symptoms of a significant number of patients with RCC improved in a short period., Competing Interests: Declaration of competing interest The authors have no conflicts of interest., (Copyright © 2024 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.)